March 5 (Reuters) - Novo Nordisk said on
Wednesday it would offer lower-priced doses of its weight loss
drug Wegovy at a reduced cost of $499 per month for cash-paying
customers.
The offer will be available for uninsured patients or
eligible patients with commercial insurance who do not have
coverage for obesity medicines, the company said.